• Portfolio

Sirigen

Oxford Capital exited its investment in Sirigen in August 2012. Sirigen was acquired by Becton, Dickinson and Company, a leading global medical technology company for $65 million.

Sirigen commercialised a novel application of conducting polymers in the medical diagnostics market. Sirigen’s technology adds “high sensitivity fluorescence” (HSF) to diagnostic techniques, as well as simplifying sample processing and instrumentation requirements. Generating sufficient signal from diagnostic tests, in order to be sure of an accurate diagnosis, is a key challenge for the diagnostic industry. By incorporating the light-harnessing power of the Sirigen polymers, the signal from the diagnostic is greatly increased.

Awards

Latest Oxford Capital News

Oxford Capital shortlisted for Most Impactful Investment at ...

Oxford Capital's investment in Push Doctor has been shortlisted for Most Impactful Investment at the...

Read more

Oxford Capital joins $10m Series A funding round in 'connect...

Curve - the UK fintech startup that combines your cards i...

Read more

Push Doctor raises $26.1M to help people live longer

Europe’s largest digital health provider, Push Doctor, today announced that it has raised $26.1M i...

Read more
More News